Psychosis in Parkinson’s and Alzheimer’s Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Psychosis in Parkinson’s and Alzheimer’s Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Psychosis in Parkinson’s and Alzheimer’s Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson’s and Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Psychosis in Parkinson’s and Alzheimer’s Disease Market by downloading the comprehensive report from DelveInsight @ Psychosis in Parkinson’s and Alzheimer’s Disease Market

 

Key Takeaways from the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report

• As per DelveInsight analysis, it is estimated that the Psychosis in Parkinson’s and Alzheimer’s Disease treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapies that are in clinical development for its treatment and due to the increasing patient pool.
• As per DelveInsight analysis, in 2023, there were approximately 15.4 million diagnosed prevalent cases of Alzheimer’s disease in the 7MM. Out of these, the US accounted for approximately 41% of the total cases, while, the EU4 and the UK accounted for the least with nearly 33% of the total, in 2023.
• As per DelveInsight analysis, there were approximately 6 million total diagnosed prevalent cases of psychosis in Alzheimer’s disease, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
• As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Parkinson’s Disease Psychosis in the 7MM were approximately 876 thousand cases. These cases are projected to increase during the forecast period (2024–2034).
• The leading Psychosis in Parkinson’s and Alzheimer’s Disease Companies such as ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
• Promising Psychosis in Parkinson’s and Alzheimer’s Disease Therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.

 

Gain a competitive edge in the Psychosis in Parkinson’s and Alzheimer’s Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Psychosis in Parkinson’s and Alzheimer’s Disease Treatment Drugs

 

Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology Segmentation in the 7MM

• Psychosis in Parkinson’s and Alzheimer’s Disease Diagnosed Prevalent Cases
• Psychosis in Parkinson’s and Alzheimer’s Disease Gender-specific Cases
• Psychosis in Parkinson’s and Alzheimer’s Disease Age-specific Cases

 

Psychosis in Parkinson’s and Alzheimer’s Disease Treatment Market

The current treatment regime involves nonpharmacological and pharmacological approaches. The primary aim of the treatment is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms. The use of typical and atypical antipsychotics are the first-line treatment (e.g., aripiprazole, clozapine, quetiapine, etc.). However, atypical antipsychotics are often considered in the initial therapy, which reduces the risk of later deterioration in patients. Apart from antipsychotics, 5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), or other antidepressants are also used.

 

Discover key developments and opportunities in the Psychosis in Parkinson’s and Alzheimer’s Disease Market. Click here to learn more from DelveInsight’s latest report @ Psychosis in Parkinson’s and Alzheimer’s Disease Market Size

 

Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights

Psychosis is also common in most people with Alzheimer’s disease throughout their illness. According to studies, over half of the people with Alzheimer’s disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.

 

Psychosis in Parkinson’s and Alzheimer’s Disease Marketed Drugs

• NUPLAZID (pimavanserin): Acadia Pharmaceuticals

 

Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Drugs

• Ulotaront (SEP-363856): Sunovion Pharmaceuticals
• KarXT (xanomeline-trospium): Karuna Therapeutics
• ITI-1284: Intra-Cellular Therapies

 

Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook

Psychosis is also common in most people with Alzheimer’s disease throughout their illness. According to studies, over half of the people with Alzheimer’s disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.

 

Download DelveInsight’s Psychosis in Parkinson’s and Alzheimer’s Disease Market report today and stay ahead in this rapidly evolving field. @ Psychosis in Parkinson’s and Alzheimer’s Disease Clinical Trials

 

Scope of the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report

• Coverage- 7MM
• Psychosis in Parkinson’s and Alzheimer’s Disease Companies- ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
• Psychosis in Parkinson’s and Alzheimer’s Disease Therapies- NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
• Psychosis in Parkinson’s and Alzheimer’s Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Psychosis in Parkinson’s and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s and Alzheimer’s Disease Market Access and Reimbursement

 

Download the report to understand which factors are driving Psychosis in Parkinson’s and Alzheimer’s Disease Market Trends @ Psychosis in Parkinson’s and Alzheimer’s Disease Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Psychosis in PD and AD Market Overview at a Glance

4. Methodology of Psychosis in Parkinson’s disease and Alzheimer’s disease Epidemiology and Market

5. Executive Summary of Psychosis in Parkinson’s disease and Alzheimer’s disease

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Psychosis in Parkinson’s disease and Alzheimer’s disease: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/